Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively perform only modestly. Our aim was to assess whether including other items from the clinical history and limited diagnostic evaluation improves their performance.
INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder, characterized by lower abdominal pain or discomfort in association with a change in stool form and/or frequency ( 1 ) . Th e condition has a prevalence of up to 20% in Western populations ( 2 ) and is associated with signifi cant morbidity. IBS results in reduced quality of life for the individual and represents a considerable economic burden to society due, in part, to the costs to health-care systems of managing the condition ( 3 ) . Th ere is an expectation that physicians should try to reduce these costs by making a positive diagnosis of IBS, using symptom-based diagnostic criteria, while simultaneously minimizing invasive investigations ( 4, 5 ) .
Physicians may be reluctant to adopt this approach in clinical practice as GI diseases manifest as a limited repertoire of Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation symptoms and those of IBS can mimic organic diseases, such as infl ammatory bowel disease ( 6 ) , microscopic colitis, ( 7 ) , bile acid diarrhea ( 8, 9 ) , or celiac disease ( 10 ) . Th e current "gold standard" for symptom-based diagnosis of IBS are the Rome III criteria ( 1 ), but these have only been validated in one large study from Canada ( 11 ) and performed modestly in distinguishing IBS from organic GI disease. However, one of the issues in diagnostic test studies for IBS is the lack of an accepted reference standard. Most investigators have used a normal colonoscopy as confi rmation of a diagnosis of IBS ( 12 ) ; that is, physicians still regard IBS as a diagnosis of exclusion, which is perhaps justifi ed by the modest performance of the diff erent symptom-based criteria for IBS proposed over the past four decades ( 11, 13 ) . Indeed, the current level of diagnostic confi dence, based exclusively on these criteria, has not reduced the performance of testing such as colonoscopy and biopsies in some settings ( 14 ) , despite the desirability to enhance high-value care.
Recently, research has focused on the development of novel fecal, serum, and imaging-based biomarkers that may more accurately predict a diagnosis of IBS or subgroups of IBS (15) (16) (17) (18) (19) . Some of the proposed biomarkers (which are unfortunately not widely available) may also serve as therapeutic targets and enhance outcomes. Despite this, a systematic review and meta-analysis that evaluated all generally available approaches to diagnose IBS demonstrated that biomarkers alone performed similarly to symptombased criteria ( 20 ) , while adding to the cost of care. Interestingly, studies using combinations of symptoms with biomarkers and/ or measures of psychological well-being reported improved diagnostic accuracy ( 17, 21 ) . Other investigators have reported that the absence of "red fl ag" features, such as nocturnal symptoms ( 22, 23 ) , or incorporating the results of simple laboratory tests, including hemoglobin and erythrocyte sedimentation rate ( 24 ) , may increase the ability to distinguish between functional and organic lower GI diseases.
Our aim, based on these observations, was to conduct a diagnostic accuracy study to examine whether the performance of the current gold-standard in symptom-based criteria for IBS could be improved if combined with other relevant markers. We hypothesized that the inclusion of the results of simple laboratory tests, absence of nocturnal symptoms, identifi cation of markers of either somatization or anxiety/depression, or combinations thereof would increase the performance of the Rome III criteria in diagnosing IBS. Proof of enhancement in the diagnostic performance of symptom-based criteria could result in a reliable, inexpensive, and easily administrable clinical evaluation and represent a considerable advance in enabling clinicians to make a positive diagnosis of IBS confi dently in the clinic.
METHODS

Participants and setting
We recruited unselected, consecutive patients aged ≥16 years newly referred from primary care to secondary care for consideration of investigation of GI symptoms. All patients were approached in six of the medical gastroenterology outpatient clinics of Leeds Teaching Hospitals Trust, West Yorkshire, UK. Th e hospitals provide secondary care services to a local population of almost 800,000 people in the North of England. Th e only exclusion criteria were an inability to understand written English, as the questionnaires utilized were self-administered. Potentially eligible subjects were given a study information sheet at their initial clinic visit, before consultation with a gastroenterologist. Th ose agreeing to participate provided written informed consent at that visit. Th e local ethics committee approved the study (reference 13/YH/0216), with recruitment commencing in January 2014 and continuing through to December 2015. During the 2-year recruitment period, the six involved clinics saw approximately 2,200 new outpatient referrals. As the study was conducted in routine clinical practice, the diagnostic evaluation of the recruited patients was not standardized and was left at the discretion of the responsible physician. We did not mandate a minimum panel of blood tests or collection of colonic biopsy specimens in all patients. However, all patients agreeing to participate were asked to complete the questionnaires detailed below. In addition, fecal calprotectin testing was not used routinely within our department during the time this study was conducted.
Data collection and synthesis
Demographic and symptom data . All demographic and symptom data were collected prospectively at the initial clinic visit. Questionnaire data were entered into a database by trained researchers who were not involved in the clinical care of the patient, thus ensuring that assessors were blinded to symptom status. Demographic data of interest included age, height (in meters), and weight (in kilograms), from which body mass index was calculated, gender, tobacco and alcohol use, marital status, educational level, and ethnicity. Th e Rome III diagnostic questionnaire for adult functional GI disorders was used to collect data on GI symptoms ( 25 ) . We also asked patients whether they experienced nocturnal passage of stool, which was recorded as occurring never, rarely, sometimes, oft en, most of the time, or always, with a symptom frequency of sometimes or greater used to defi ne its presence.
Mood and somatization data . We used the validated hospital anxiety and depression scale (HADS) to collect information about mood ( 26 ) . Th is 14-item instrument contains 7 questions concerning anxiety and another 7 concerning depression. Each of these questions is scored from 0 to 3, giving a total possible score of 21 for anxiety or depression separately. A score of ≥8 was used to defi ne possible anxiety or depression.
We used the validated patient health questionnaire-15 to assess for evidence of somatization-type behavior ( 27 ) . Th e individual symptom items are provided in Supplementary Table S1 online. Each of these questions is scored on a scale from 0 to 2, giving a total possible score of 30. A score of ≥15 is the validated threshold used to defi ne high levels of somatization.
Baseline tests in diagnostic evaluation . We also collected information from patients' case notes and computerized records. We recorded hemoglobin level (normal for males ≥13.5 g/dl, FUNCTIONAL GI DISORDERS VOLUME 111 | OCTOBER 2016
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normal for females ≥11.5 g/dl) and C-reactive protein (CRP) (normal <5 mg/l) at the initial clinic visit. We also recorded the initial diag nosis made by the physician who consulted with the patient, as well as the fi nal diagnosis made aft er investigation to the level deemed appropriate by each individual consulting physician.
Defi nition of IBS . Th e presence or absence of Rome III-defi ned IBS among individual patients was assigned according to the scoring algorithm proposed for use with the Rome III questionnaire ( Supplementary Table S2 ).
Colonoscopic and histopathological data . All included patients underwent complete colonoscopy to the cecum or terminal ileum. Th e endoscopy units in Leeds Teaching Hospitals Trust employ colonoscopes from both Olympus (Southend-on-Sea, UK) and Fujinon (Bedford, UK). Bowel preparation was either a combination of polyethylene glycol and sodium picosulfate or polyethylene glycol alone, depending on renal function. All endoscopists performing colonoscopic examinations remained blinded to the questionnaire data of the patient. Findings were recorded using the ADAM reporting system (Fujifi lm, Dusseldorf, Germany), with reports accessed by study investigators in order to record the fi nal colonoscopic diagnosis for each included patient. Findings classifi ed as consistent with organic disease at colono scopy are provided in Table 1 .
Biopsy specimens were obtained at the discretion of the endoscopist performing the colonoscopy. Standard policy during these colonoscopies in any patient with chronic diarrhea and a macroscopically normal colon is to take two biopsies from the right colon, two from the left colon, and two from the rectum. All biopsies were interpreted by experienced GI histopathologists, who remained blinded to the questionnaire data of the patient. Histopathological fi ndings were accessed using computerized records to record the fi nal histopathological diagnosis. Findings classifi ed as being consistent with organic disease aft er histopathological exami nation of biopsy specimens are also provided in Table 1 .
Using these data, patients were classifi ed according to the presence or absence of organic lower GI disease. Individuals had to have no evidence of an organic explanation for their symptoms at both colonoscopy and histopathological examination of biopsy specimens in order to be classifi ed as exhibiting no organic lower GI disease.
Reference standard to defi ne the presence of true IBS
Th e reference standard used to defi ne the presence of true IBS was lower abdominal pain or discomfort occurring at least 3 days per month over the past 3 months, in association with a change in bowel habit, and in the absence of organic lower GI disease aft er colonoscopy and histopathological examination of colonic biopsies, if obtained, which would explain these symptoms. Exclusion of celiac disease with distal duodenal biopsy was also undertaken, if celiac serology was positive.
Statistical analysis
In order to assess whether those who underwent colonoscopy and provided complete symptom data were representative of all patients recruited, demographic data were compared between those undergoing colonoscopy who completed the symptom questionnaire and those who completed the symptom questionnaire but did not undergo colonoscopy, using a χ 2 test for categorical data and an independent samples t -test for continuous data, with a mean and s.d. Because of multiple comparisons, a twotailed P value of <0.01 was considered statistically signifi cant for these analyses. We compared organic fi ndings in those meeting the Rome III criteria for IBS with those who did not, using Fisher's exact test, as numbers in each cell were relatively small. Th ese statistical analyses were performed using SPSS for Windows version 21.0 (SPSS, Chicago, IL).
Th e fi rst aim of the study was to ascertain the performance of the Rome III criteria for IBS in determining the presence of true IBS vs. the reference standard of symptoms suggestive of IBS and a negative colonoscopy described above. To that end, sensitivity, specifi city, and positive and negative predictive values, and their 95% confi dence intervals (CIs), were calculated for the Rome III criteria vs. the reference standard using StatsDirect version 2.8.0 (StatsDirect, Sale, Cheshire, England). Th e positive likelihood ratio (LR) and negative LR, and their 95% CIs, were also calculated. Th e positive LR can be calculated from the formula: positive LR=sensitivity/(1-specifi city). Th e negative LR is derived from the formula: negative LR=(1−sensitivity)/specifi city. We performed these analyses for all individuals recruited who underwent colonoscopy for investigation of their lower GI symptoms and provided complete Rome III symptom data. However, in clinical practice the challenge is oft en in distinguishing between IBS-D and other potential organic GI causes of diarrhea. With this in mind, we performed post-hoc analyses including only those participants reporting either ≥4 stools per day or loose, mushy, or watery stools.
Th e advantage of using LRs over predictive values is that LRs do not vary to the same degree as predictive values with a change in disease prevalence. As a rule of thumb, a positive LR of >10 is useful for ruling in a disease and a negative LR of <0.1 is useful for ruling out a disease. However, in diseases of higher prevalence, the positive LR threshold required to cause a useful increase in probability that will result in a change of management may be lower. In a recently published systematic review, the authors assumed "medical certainty" for a novel biomarker in diagnosing IBS as a posttest probability (derived from the pretest probability and positive LR) of > 80% ( 28 ) . At this threshold, in a secondary or tertiary care population with a prevalence of IBS of around 50%, a test with a positive LR of ≥5 would identify IBS with a posttest probability of 86.5%. Th e second aim was to compare the performance of proposed modifi cations to the Rome III criteria, by including information on nocturnal passage of stools, the physician's working diagnosis at the initial consultation, laboratory results of hemoglobin and CRP, and measures of anxiety/depression and somatization against the reference standard described above. Again, sensitivities, specifi cities, positive and negative predictive values, and positive and negative LRs were calculated for each of these modifi cations individually and as combinations.
RESULTS
Th ere were 1,002 consecutive patients (mean age 54.4 years (range 16-92 years), 638 (63.7%) female) who gave informed consent and were recruited into the study between January 2014 and December 2015. Of these, 318 (31.7%) patients (mean age 54.0 years (range 18-92 years), 216 (67.9%) female) underwent colonoscopy for investigation of their lower GI symptoms and provided complete Rome III symptom data ( Figure 1 , fl ow chart) .
Comparison of the demographic data of this group with those who did not undergo colonoscopy is provided in Table 2 . Patients providing complete symptom data and undergoing colonoscopy had a higher body mass index and were more likely to meet the Rome III criteria for IBS, but there were no other signifi cant diff erences between the two groups. Patients with IBS with diarrhea (IBS-D) were more likely to undergo colonoscopy but not patients with IBS with constipation or those with mixed stool pattern IBS.
Among the 318 individuals providing complete symptom and colonoscopy data, 98 (30.8%) met the Rome III criteria for IBS. Th e mean age of these 98 patients was 46.7 years and 73 (74.5%) were female. Th ere were 286 (89.9%) patients who had a hemoglobin check, 178 (56.0%) with a CRP measurement, 212 (66.7%) with celiac serology, and 215 (67.6%) who had colonic biopsy specimens obtained. Relevant organic fi ndings aft er colonoscopy and histopathological interpretation of biopsy specimens, plus Note that, for all these combinations, positive LRs were above the threshold of ≥5 that has been recommended to defi ne a potentially useful test, providing the prevalence of IBS in the population under study is ≥50% ( 28 ) . Specifi city approached ≥95% with all these modifi cations; thus the risk of a missed diagnosis of organic GI disease would be small, as the false positive rate was extremely low.
When the analyses were restricted to participants who reported either ≥4 stools per day or loose, mushy, or watery stools, there were similar enhancements of positive LRs (in some instances, almost twofold those for the Rome III criteria alone) with the incorporation of additional factors from the clinical history and simple laboratory tests into the Rome III criteria ( Table 5 ).
DISCUSSION
Th is study validated the symptom-based Rome III criteria for IBS against an accepted clinical reference standard. Th ese criteria performed modestly, with a positive and negative LR of 3.87 and 0.37, respectively. In addition, we examined the eff ect of addition of nocturnal symptoms, factors related to somatization, aff ective disorders, and hemoglobin and CRP measurements on the accuracy of the symptom-based Rome III criteria. A combination of the Rome III criteria with a high level of somatization, a normal hemoglobin and CRP with a HADS score of ≥8, a normal hemoglobin and CRP with a high level of somatization, or no nocturnal passage of stool with a high level of somatization all provided positive LRs of ≥5. In a secondary or tertiary referral population in a University Hospital practice with a prevalence of IBS of ≥50%, a positive LR of this magnitude would be clinically useful for the diagnosis of IBS, identifying IBS with a posttest probability of >85% ( 28 ) .
Th e performance of the Rome III criteria in this study is remarkably similar to that observed in a previous validation study, which also used a reference standard of the combination of symptoms suggestive of IBS and a negative colonoscopy ( 11 ) . In that prior study from Canada ( 11 ), which included >1,800 patients, the positive and negative LRs of the Rome III criteria were 3.35 (95% CI 2.97-3.79) and 0.39 (95% CI 0.39-0.46), respectively. Unlike the current study, the previous study did not incorporate other features of the clinical history or simple laboratory tests with the Rome III criteria. Sensitivity analyses were conducted in the Canadian study ( 11 ) , where individuals reporting lower GI alarm symptoms, including rectal bleeding, anemia, weight loss, or a family history of colorectal cancer, were excluded. However, the addition of lower GI alarm symptoms resulted in only a small improvement in the positive LR. Few other studies have attempted to modify the symptom-based Rome criteria ( 22 ) . Vanner et al. ( 22 ) examined the eff ect of excluding patients with "red fl ag" features, including nocturnal GI symptoms, on the Rome I criteria. However, this was a small retrospective study, and the investigators did not duodenal biopsy in those with positive celiac serology, in those who met the Rome III criteria compared with the 220 patients who did not are detailed in Table 3 . Th ere were no signifi cant diff erences in the prevalence of any of these between the two groups.
Performance of the Rome III criteria for IBS against the reference standard
Of the 79 (24.8%) individuals meeting the reference standard of symptoms suggestive of IBS and a negative colonoscopy, 55 met the Rome III criteria, giving a sensitivity of 69.6% ( Table 4 ) . Among the 239 patients without IBS according to this reference standard, 196 did not meet the Rome III criteria, giving a specifi city of 82.0%. Positive and negative LRs of the Rome III criteria were 3.87 (95% CI 2.85-5.26) and 0.37 (95% CI 0.26-0.51), respectively.
Effect of additional factors from the history and simple laboratory tests on the diagnostic performance of Rome III criteria
Th e eff ect of incorporating nocturnal passage of stools, a physician's working diagnosis at the initial consultation that this was IBS, the presence of anemia or a raised CRP, HADS score of ≥8, or high levels of somatization into the Rome III criteria are also shown in Table 4 . Sensitivities in diagnosing IBS ranged from 18.2% for the presence of Rome III criteria, no nocturnal passage of stool, and a high level of somatization to 50.0% for the presence of the Rome III criteria and a physician's initial impression that the diagnosis was IBS. Specifi cities ranged from 79.7% for presence of the Rome III criteria and a physician's initial impression that the diagnosis was IBS to 99.0% for presence of the Rome III criteria, no nocturnal passage of stool, and a high level of somatization.
Improved positive LRs were obtained by combining the Rome III criteria with a high level of somatization alone (positive LR 7.27; 95% CI 3.74-14.2); a normal hemoglobin and CRP with a 
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Enhancing Clinical Diagnosis of IBS attempt to separate nocturnal GI symptoms from other alarm symptoms, which are reported frequently by patients without organic disease ( 29 ) . Psychological or aff ective disorders have been shown to be strongly associated with IBS ( 30 ) . Th ere was an improvement in diagnostic test accuracy when other investigators added these to a biomarker panel in a recent study ( 17 ) . Rates of somatoform-type behavior, in particular, have been shown to be signifi cantly higher in patients with IBS ( 31 ) and to diff erentiate IBS from health with greater accuracy, compared with markers of anxiety and depression ( 32 ) . Th e results of our study support this fi nding, with a greater accuracy when a combination of the Rome III criteria and high level of somatization was used, as compared with a combination of the Rome III criteria and HADS scores. Incorporating the presence of co-existent functional GI disorders into our modifi cations to the Rome III criteria may also have improved their performance. However, unlike in IBS, some other functional GI disorders are diagnoses of exclusion. For instance, a diagnosis of functional heartburn would not be made on symptoms alone but only aft er a negative upper endoscopy and normal pH and impedance studies. As our study did not mandate the relevant investigations to confi rm that, when the appropriate symptoms were reported, the cause was indeed another functional GI disorder, we were therefore unable to examine this issue.
We propose that the performance of the modifi cations to the Rome III criteria used in the current study can be best appreciated by comparing them with the accuracy of biomarkers. In general, biomarkers have been shown to perform no better than symptom-based diagnostic criteria in IBS ( 20 ) and, in some cases, are probably not clinically useful outside of a research or tertiary care setting, owing to their complex or invasive nature, e.g., brain imaging, or endoscopy and biopsy with specialized histopathology (33) (34) (35) (36) . Furthermore, many of the studies that have validated biomarkers have been limited by the fact that their utility in IBS was compared with healthy controls, when it would be more useful to assess the performance of the biomarker in distinguishing between IBS and organic disease. Alternatively, other appraisals of biomarkers have used IBS-enriched populations, reducing their generalizability to a clinical setting ( 20 ) .
One biomarker that is available for use in clinical practice currently was examined for its ability to diff erentiate IBS-D from infl ammatory bowel disease, celiac disease, or health ( 19 ) . In this model in 1984 and outperformed symptom-based diagnostic criteria alone in a previous meta-analysis ( 12 ) . Tibble et al. ( 21 ) also demonstrated a high diagnostic accuracy of the Rome I criteria in combination with both a fecal calprotectin and a small intestinal permeability ratio. However, the model by Kruis et al. ( 24 ) may be limited by its complexity, and the approach of Tibble et al. ( 21 ) is not clinically applicable, given the lack of availability of measures of small intestinal permeability. We suspect that the proposed models did not progress beyond a research setting because of their complexity. Other markers for measurement of small intestinal and colonic permeability have been proposed since the earlier study by Tibble et al. , ( 21 ) based on the ratio of saccharide excretion ( 37 ), although there is still no generally available, clinically applicable, and universally accepted test of intestinal permeability at present.
Th ere are methodological strengths of our study. First, it was conducted in a large, unselected population referred to secondary care, so the results are likely to be generalizable to patients with suspected IBS seen in usual clinical care by gastroenterologists. Th e sample size, although smaller than the previous validation study of the Rome III criteria ( 11 ) , is larger than most other studies that have assessed the accuracy of diagnostic tests for IBS ( 20 ) . study, antibodies to cytolethal toxin B, a toxin commonly produced by Campylobacter jejuni , and to vinculin, a cell adhesion protein, performed best when diff erentiating IBS-D from infl ammatory bowel disease, with positive LRs of 5.2 and 2.0, respectively. However, the authors used an enriched sample of cases, which consisted of a cohort of patients enrolled in a large randomized clinical trial of rifaximin, with >80% of participants having IBS-D. Th us the LRs may not be reproducible in other populations or in those with IBS not associated with diarrhea. Th is underlines the importance of our fi ndings in a consecutive, unselected secondary care population where various combinations of the Rome III criteria, two routine blood tests, and a symptom-item checklist appeared accurate and would be inexpensive to administer as a diagnostic test.
Th e improved performance of the Rome III criteria when combined with relevant blood tests and markers of somatization and anxiety/depression is perhaps not surprising given the fi ndings of other investigators, summarized in a recent meta-analysis ( 20 ) . Studies that have used symptoms with clinical laboratory tests, biomarkers, and markers of psychological disorders have shown improved diff erentiation of IBS from organic GI diseases. Th is direction was fi rst suggested by Kruis et al. ( 24 ) in a statistical 
Enhancing Clinical Diagnosis of IBS Second, it was designed to adhere to the STARD guidelines for the reporting of studies of diagnostic accuracy, with consecutive patients recruited, assessors blinded, and accepted references standard used. Th ird, it used inexpensive factors to modify the symptom-based criteria, and these lend themselves to application in primary or secondary care.
Th ere are some limitations to the study. Not all patients that underwent colonoscopy provided complete symptom data, and we were therefore unable to include these individuals in our analyses. However, this number was comparatively small, with almost 90% of patients providing full data. Most of the patients included in the study were White Caucasian, meaning that these results may not be applicable to other ethnicities. Th e mean age of included individuals was relatively high at 54 years, which probably refl ects our use of a negative colonoscopy as a reference standard, meaning that there is some selection bias and that the results may therefore not be generalizable to a younger population. In addition, the reference standard we used in our analyses included symptom data from the questionnaire, which may have resulted in an overestimation of the accuracy of the Rome III criteria and its modifi cations, and a negative colonoscopy. Th ere are other conditions that may mimic IBS, such as bile acid diarrhea, small intestinal bacterial overgrowth, or fructose and lactose intolerance (38) (39) (40) , which are not excluded by a negative colonoscopy. Th ese were not screened for routinely in this study, which was conducted within usual clinical practice. However, the prevalence of unequivocal small intestinal bacterial overgrowth in patients presenting with symptoms suggestive of IBS is probably <5% ( 41 ) . For similar reasons, we did not mandate a minimum diagnostic work up in terms of a panel of standardized blood tests or colonic biopsy specimens in all patients. Th e modifi cations to symptom-based criteria in our current study enhanced the diagnosis of IBS but do not necessarily identify actionable features of the disorder. Th us the recently validated additional measurements of colonic transit or of bile acid metabolism still provide the best biomarkers to individualize therapy in subsets of IBS patients ( 18, 42 ) . Finally, the approaches suggested by our fi ndings may not completely change physician behavior, owing to uncertainty or fear of a missed organic diagnosis, which is refl ected by the fact that signifi cantly more patients who met the Rome III criteria for IBS were referred for colonoscopy in this study. However, further proof of the validity of this approach in prospective cohorts will enhance the confi dence with which physicians can make a positive diagnosis of IBS, which was the intent of the original symptom-based criteria proposed by Manning et al. ( 13 ) .
In summary, the performance of the Rome III criteria in diagnosing IBS was similar to that observed in a previous validation study from a cohort in Canada ( 11 ) . Important novel fi ndings from this study were that modifying these criteria, with questionnaires concerning nocturnal symptoms, anxiety/depression, and somatization, in addition to simple laboratory tests, improved their diagnostic performance. An inexpensive clinical test that combines symptoms with clinical markers, which is easily administered in a routine care setting, and accurate enough to allow the physician to confi dently make a positive diagnosis of IBS would be highly desirable and may have important implications for enhanced value care.
